New antipsychotics, compliance, quality of life, and subjective tolerability - Are patients better off?

Canadian Journal of Psychiatry

Volumn 49, Issue 5, 2004, Pages 297-302

  Awad, A George ^a,c   Voruganti, Lakshmi N P ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c Department of Psychiatry ^*  (Canada)

Author keywords

Antipsychotics; Medication adherence; Neuroleptic dysphoria; Quality of life; Schizophrenia; Subjective tolerability

Indexed keywords

ARIPIPRAZOLE; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; REMOXIPRIDE; RISPERIDONE; ZIPRASIDONE;

DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPHORIA; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; PATIENT SATISFACTION; QUALITY OF LIFE; REVIEW; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 2642587986     PISSN: 07067437     EISSN: None     Source Type: Journal    
DOI: 10.1177/070674370404900504     Document Type: Review

References (62)

1. Awad AG, Voruganti LNP, Heslegrave RJ. The aim of antipsychotic medications: what are they and are they being achieved? CNS Drugs 1995;4:8-16.
2. Leuchts S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side effects of the new antipsychotics olanzapine, quetiapine, risperidone and sertindole, compared to conventional antipsychotics and placebo-a meta-analysis of randomized control trials. Schizophr Res 1999;35:51-68.
3. Meyer JM. Novel antipsychotics and severe hyperlipidemia. J Clin Psychopharmacol 2001;21:369-74.
4. Wirshing DA, Spellberg BJ, Erhart SM, Olander SR, Wirshing WC. Novel antipsychotics and new onset diabetes. Biol Psychiatry 1998;44:778-83.
5. Meltzer HY, Davidson M, Glassman AH, Vieweg WVR. Assessing cardiovascular risks versus clinical benefits of atypical drug treatment. J Clin Psychiatry 2002;63:25-9.
6. Haynes RB, Taylor DW, Sachett DL. Compliance in health care. Baltimore (MD): Johns Hopkins University Press; 1979.
7. Corrigan PW, Lieberman RP, Engel JD. From non-compliance to collaboration in treatment of schizophrenia. Hosp Community Psychiatry 1990;41:1203-11.
8. Awad AG, Masty V, McDonnell D. The link between drug attitudes, compliance behaviours and resource use among individuals with schizophrenia. Poster presented at the 152nd American Psychiatric Association Meeting; 1999; Washington (DC).
9. Awad AG. Antipsychotic medications: compliance and attitudes toward treatment. Curr Opin Psychiatry. Forthcoming.
10. Baldessarini R. Enhancing treatment with psychotropic medications. Bull Menninger Clin 1994;58:224-41.
11. Fenton WS, Blyler CR, Heinssen R. Determinants of medication compliance in schizophrenia. Empirical and clinical findings. Schizophr Bull 1997;23:637-51.
12. Perkins DO. Adherence to antipsychotic medications. J Clin Psychiatry 1999;60 (Suppl 21):25-30.
13. Barnes T, Andrews D, Awad AG. Poor compliance in treatment in people with schizophrenia: causes and management. In: Buckley P, Waddington J, editors. Schizophrenia and mood disorders - the new drug therapies in clinical practice. Oxford (UK): Butterworth and Heinman; 2000. p 317-39.
14. Lacro J, Dunn L, Dolder C, Leckband S, Jeste D. Prevalence and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002;63:892-909.
15. Voruganti LNP, Cortese L, Oyewumi L, Kotteda V, Cernovsky Z, Zirul S, and others. Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study. Schizophr Res 2002;57:201-8.
16. Boulanger L, Friedman H, MacKell J, Lloyd J. Treatment adherence associated with conventional and atypical antipsychotic in a large state Medicaid program. Psychiatr Serv 2003;54:719-23.
17. Cabeza TG, Amador MS, Lopez CA. Subjective response to antipsychotics in schizophrenic patients: clinical implications and related factors. Schizophr Res 2000;41:349-55.
18. Olfson M, Mechamic D, Hansell S. Predicting medication non-compliance after hospital discharge among patients with schizophrenia. Psychiatr Serv 2000;512:216-22.
19. Grunëbaum MF, Weiden PJ, Olfson M. Medication supervision and adherence with psychotic disorders in residential treatment settings: a pilot study. J Clin Psychiatry 2001;62:394-99.
20. Weiss K, Smith T, Hull J. Predictors of risk of non-adherence in outpatients with schizophrenia and other psychiatric disorders. Schizophr Bull 2002;28:341-9.
21. Rosenheck R, Cramer J, Xu W, Henderson W, Frisman L, Fye C, and others. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. New Engl J Med 1977;337:809-15.
22. Awad AG, Voruganti LNP, Heslegrave RJ. Measuring quality of life in patients with schizophrenia. Pharmacoeconomics 1997;11:32-47.
23. Awad AG. Quality of life in schizophrenia. In: Lader M, editor. Psychiatry highlights 2001-2002. Oxford (UK): Health Press Ltd; 2002. p 36-41.
24. Awad AG, Voruganti LNP, Heslegrave RJ. A conceptual model of quality of life in schizophrenia: description and preliminary clinical validation. Quality of Life Res 1997;6:21-6.
25. Lehman AF. Convergent validation of quality of life assessments for persons with severe mental illness. Quality of Life Res 1993;2:327-33.
26. Awad AG, Hogan TP. Subjective response to neuroleptics and quality of life-implications for treatment outcome. Acta Psychiatr Scand 1994;89(Suppl 380):27-32.
27. Franz M, Pluddeman K, Gallhofer B. Conventional versus atypical neuroleptics in subjective quality of life in schizophrenia patients. Br J Psychiatry 1997;170:422-5.
28. Voruganti LNP, Cortese L, Ouyewumi L, Chemovsky Z, Zirul S, Awad AG. Comparative evaluation of conventional and new antipsychotic drugs with reference to their subjective tolerability, side effects profile and impact on quality of life. Schizophr Res 2000;43:135-45.
29. Awad AG, Voruganti LNP. The impact of new antipsychotics on quality of life. CNS Drugs. Forthcoming.
30. Jeste DV, Klausner M, Brecher M. A clinical evaluation of of risperidone in the treatment of schizophrenia-a ten-week open-label multicentre trial. Psychopharmacol 1997;131:239-47.
31. Bobes J, Gutierrez M, Gibert J. Quality of life in schizophrenia: long-term follow-up in 362 chronic Spanish schizophrenic outpatients undergoing risperidone maintenance treatment. Eur Psychiatry 1998;13:158-68.
32. Tran PV, Hamilton SH, Kunz AJ, Potvin JH, Andersons W, Beasley C Jr, and others. Double-blind comparison of olanzapine verses risperidone in the treatment of schizophrenia and other psychiatric disorders. J Clin Psychopharmacol 1997;17:407-18.
33. Ho BC, Miller D, Nopoulos P, Andreason NC. A comparative effectiveness study of risperidone and olanzapine in the treatment of schizophrenia. J Clin Psychiatry 1999;60:658-63.
34. Revicki DA, Ginduso LA, Hamilton SH, Ganoczy D, Beasley Jr C. Olanzapine vs haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial. Quality of Life Research 1999;8:417-26.
35. Hamilton SH, Revicki DA, Edgel L, Genduso LA, Tollefson GD. Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia-results from a randomized clinical trial. Pharmacoeconomics 1999;15:469-80.
36. Naber D, Moritz S, Lambert M. Improvement of schizophrenic patients subjective well-being under atypical antipsychotic drugs. Schizophr Res 2001;50:79-88.
37. Meltzer HY, Burnett S, Bastani B. Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hosp Community Psychiatry 1990;41:892-7.
38. Meltzer HY, Okayli G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk benefit assessment. Am J Psychiatry 1995;152:183-90.
39. Cook P, Goldberg J, Van Lieshout R. Benefits of switching from typical to atypical antipsychotic medications: a longitudinal study in a community-based setting. Can J Psychiatry 2002;47:870-4.
40. Awad AG, Lapierre YD, Angus C, Rylander A. Quality of life and response of negative symptoms in schizophrenia to haloperidol and the atypical antipsychotic remoxipride. J Psychiatry Neurosci 1997;22:244-8.
41. Tempier R, Pawliuk N. Influence of novel and conventional antipsychotic medications on subjective quality of life. J Psychiatry Neurosci 2001;26:131-6.
42. Essock SM, Hargreaves WA, Covell NH, Goethe J. Clozapine's effectiveness for patients in state hospitals: results from a randomized trial. Psychopharmacol Bull 1996;32:683-97.
43. Awad AG, Voruganti LNP. Quality of life and new antipsychotics in schizophrenia: are patients better off? Int J Soc Psychiatry 1999;45:268-75.
44. Van Putten T. Subjective response as a predictor of outcome in pharmacotherapy. Arch Gen Psychiatry 1978;35:477-80.
45. Van Putten T, May PRA, Marder S, Wittmann LA. Subjective response to antipsychotic drugs. Arch Gen Psychiatry 1981;38:187-90.
46. Awad AG. Subjective response to neuroleptics in schizophrenia. Schizophr Bull 1993;19:609-18.
47. Awad AG. Behavioural and subjective effects. In: Kane JM, editor. Managing the side effects of drug therapy in schizophrenia. London (UK): Science Press Ltd; 1999. p 1-14.
48. Voruganti LNP, Awad AG. Neuroleptic dysphoria - toward a new synthesis. Psychopharmacology 2004;171:121-32.
49. Awad AG, Hogan TP. Early treatment events and prediction of response to neuroleptics in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 1985;9:585-8.
50. Awad AG, Hogan TP, Voruganti LNP, Heslegrave RJ. Patients' subjective experience on antipsychotic medications: implications for outcome and quality of life. Int Clin Psychopharmacol 1995;10(Suppl 3):123-33.
51. Naber DA. Self-rating scale to measure subjective effects of neuroleptic drugs, relationship to objective psychopathology, quality of life and other clinical variables. Int Clin Psychopharmacol 1995;10(Suppl 3):133-8.
52. Voruganti LNP, Heslegrave RJ, Awad AG. Quality of life measurement during antipsychotic drug therapy of schizophrenia. J Psychiatry Neurosci 1997;22:267-74.
53. Brownie S, Gervan J, Gervin M, Roe M, Larkin C, O'Callaghan E. Quality of life in schizophrenia: insight and subjective response in schizophrenia. J Nerv Ment Dis 1998;186:74-8.
54. Bartko G, Herczeg I, Bekesy M. Predicting outcome of neuroleptic therapy on the basis of subjective response and early clinical improvement. J Clin Psychiatry 1987;48:363-5.
55. Weiden PJ, Mann JJ, Dixon L, Haas G, DeChillo N, Francis AJ. Is neuroleptic dysphoria a healthy response? Compr Psychiatry 1989;30:546-52.
56. Hellewell JS, Kalali AH, Langham SJ, Awad AG. Patient satisfaction and acceptability of long-term treatment with quetiapine. Int J Psychiatry Clin Pract 1999;3:105-13.
57. Rabinowitz J, Bromet EJ, Davidson M. Comparison of patient satisfaction and burden of adverse effects with novel and conventional neuroleptics: a naturalistic study. Schizophr Bull 2001;27:597-600.
58. Bartko G, Varadi H, Simon L, Linka E, Tuske T, Szabo T, and others. Patient satisfaction after switching from conventional to new atypical antipsychotics in schizophrenia. Int J Psychiatry Clin Pract 2002;6:9-14.
59. Steinert T. Which neuroleptic would psychiatrists take for themselves or their relatives? Eur Psychiatry 2003;18:40-1.
60. Voruganti L, Slomka P, Zabel P, Costa G, So A, Matter A, and others. Subjective effects of AMPT-induced dopamine depletion in schizophrenia: the correlation between D2 binding ratio and dysphoric responses. Neuropsychopharmacology 2001;25:642-50.
61. Kapur S, Seeman P. Does fast dissociation from the D2 receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry 2001;158:360-9.
62. de Haan L, Lavalaye J, Linszen D, Dingemans PMAJ, Booij J. Subjective experience and striatal dopamine D2 receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone. Am J Psychiatry 2000;157:1019-20.